Last update 28 Mar 2025

Luxeptinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CG-026806, CG-806, CG=E2=80=99806
+ [1]
Action
inhibitors
Mechanism
BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), FLT3 inhibitors(Tyrosine-protein kinase receptor FLT3 inhibitors)
Active Indication
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC26H19F4N5O2
InChIKeyBOLRZWTVMUHQQU-UHFFFAOYSA-N
CAS Registry1370466-81-1

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
High Risk Myelodysplastic SyndromePhase 1
United States
06 Oct 2020
Refractory acute myeloid leukemiaPhase 1
United States
06 Oct 2020
Chronic lymphocytic leukaemia refractoryPhase 1
United States
30 Apr 2019
Non-Hodgkin LymphomaPhase 1
United States
30 Apr 2019
Small Lymphocytic LymphomaPhase 1
United States
30 Apr 2019
Hematologic NeoplasmsPhase 1--
B-Cell LymphomaPreclinical
United States
19 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
35
lyisiikerr(qooblwctsp) = include decreased neutrophil count (n=6, 17.1%), decreased white blood cell count, decreased platelet count, diarrhea, anemia, and leukocytosis (n=2, 5.7% each), and increased ALT, headache, neutropenia, hyperhidrosis, hypertension, and neutropenic sepsis (n=1, 2.9% each) kjezytgqyz (qbnaezudda )
Positive
15 Nov 2022
Phase 1
25
tgteutikzj(kfwdfhsufq) = One patient reported a single DLT at 450 mg (grade 3 pericardial effusion, out of 6 patients dosed at 450 mg) and another at 750 mg (grade 3 encephalopathy, out of 10 patients dosed at 750 mg). No DLT was reported at any other dose levels through 900 mg. cqarnonoqj (awvvfcdzaq )
Positive
15 Nov 2022
Phase 1
-
zlldggrhwf(sqhcnqokwt) = neutropenia (n=5, 21.7%), leukocytosis (n=2, 8.7%), decreased white blood cell count, decreased platelet count, anemia, increased alanine aminotransferase, diarrhea, hypertension, and headache (n=1, 4.3 % each) lkmsrwjcle (mewkwqwgse )
Positive
05 Nov 2021
Phase 1
-
byshiqsfvp(pferhteecv) = rdasmjwndy sqhjkpkjax (uegdfpzqtq )
-
15 Aug 2020
Venetoclax
dugjguimrq(wgljdkzhlb) = gdlvkgdeek zinesnnwik (nqiujzigcu )
Phase 1
6
zhhiptmrin(ocisreyumn) = nufklpkdhn nemqxuqchq (qtqgapxjye )
-
14 May 2020
zhhiptmrin(ocisreyumn) = xqeztpbdgy nemqxuqchq (qtqgapxjye )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free